Balancing Risk, Cost, and Access: Early Access Programmes and Competing Policy Objectives in the EU

European Health and Pharmaceutical Law Review · Published 2026-01-01 · DOI 10.21552/ehpl/2026/1/5

Authors being retrieved — see the publisher record. https://doi.org/10.21552/ehpl/2026/1/5

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2026

Related articles

Regulatory Sandbox to Support Innovation in the Pharmaceutical Field · European Health and Pharmaceutical Law Review · 2025 · Same journal
Improving Access to Orphan Medicines: Towards a Pharmaceutical Duty of Care · European Health and Pharmaceutical Law Review · 2025 · Same journal
AI in Healthcare as a Lens on Regulatory and Governance Culture: Europe vs. Australia · European Health and Pharmaceutical Law Review · 2025 · Same journal
EHDS-as-a-Service? Commercial Challenges Unravelled · European Health and Pharmaceutical Law Review · 2026 · Same journal
Should Europe Adopt a Policy Like the US MODERN Labeling Act? · European Health and Pharmaceutical Law Review · 2023 · Same journal
Supply of Investigational Medicinal Product after the Conclusion of Clinical Trials: The Times They Are A-Changin' · European Health and Pharmaceutical Law Review · 2025 · Same journal
Clearly Defining Responsibilities and Practical Solutions to Empower Data Subjects in the EHDS: Do Health Data Access Bodies Come to the Rescue? · European Health and Pharmaceutical Law Review · 2025 · Same journal
An Overview of the Rules Governing Over-The-Counter Medicines in 30 European Countries · European Health and Pharmaceutical Law Review · 2022 · Same journal
The Supplementary Protection Certificate for Medicinal Products: Recent Developments and Outlook · European Health and Pharmaceutical Law Review · 2022 · Same journal
GDPR and Processing Health Data in Insurance Relationships: The Role of Statutory Legal Bases · European Health and Pharmaceutical Law Review · 2022 · Same journal